Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.21 and traded as high as $1.54. Accelerate Diagnostics shares last traded at $1.47, with a volume of 48,383 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on shares of Accelerate Diagnostics in a report on Thursday. They issued a “hold” rating on the stock.
Check Out Our Latest Stock Report on Accelerate Diagnostics
Accelerate Diagnostics Trading Up 4.8 %
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.05. The company had revenue of $2.99 million for the quarter, compared to analyst estimates of $3.00 million. On average, equities research analysts anticipate that Accelerate Diagnostics, Inc. will post -2.14 EPS for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Accelerate Diagnostics stock. Griffin Asset Management Inc. raised its position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) by 1.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the period. Griffin Asset Management Inc. owned 6.26% of Accelerate Diagnostics worth $1,615,000 as of its most recent filing with the SEC. Institutional investors own 17.14% of the company’s stock.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Featured Articles
- Five stocks we like better than Accelerate Diagnostics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- EV Stocks and How to Profit from Them
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What Investors Need to Know to Beat the Market
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.